[HLFG] QoQ Annualized Quarter Result on 31-Dec-2017 [#2]

Announcement Date
26-Feb-2018
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2018
Quarter
31-Dec-2017 [#2]
Profit Trend
QoQ- 4.4%
YoY- 14.64%
View:
Show?
Annualized Quarter Result
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
Revenue 5,532,660 5,350,991 5,374,829 5,289,534 5,115,008 5,034,562 5,015,330 6.75%
PBT 3,716,424 3,578,585 3,610,610 3,530,378 3,361,844 3,089,949 3,095,764 12.94%
Tax -637,996 -684,059 -675,450 -650,630 -601,496 -773,065 -596,524 4.57%
NP 3,078,428 2,894,526 2,935,160 2,879,748 2,760,348 2,316,884 2,499,240 14.89%
-
NP to SH 2,022,780 1,907,442 1,937,536 1,901,190 1,821,008 1,506,765 1,663,961 13.88%
-
Tax Rate 17.17% 19.12% 18.71% 18.43% 17.89% 25.02% 19.27% -
Total Cost 2,454,232 2,456,465 2,439,669 2,409,786 2,354,660 2,717,678 2,516,090 -1.64%
-
Net Worth 18,182,568 17,796,897 17,622,136 17,327,505 17,109,476 16,661,945 16,616,044 6.18%
Dividend
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
Div 595,398 457,798 609,894 298,354 596,708 436,056 581,408 1.59%
Div Payout % 29.43% 24.00% 31.48% 15.69% 32.77% 28.94% 34.94% -
Equity
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
Net Worth 18,182,568 17,796,897 17,622,136 17,327,505 17,109,476 16,661,945 16,616,044 6.18%
NOSH 1,147,516 1,147,516 1,147,516 1,147,516 1,147,516 1,147,516 1,147,516 0.00%
Ratio Analysis
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
NP Margin 55.64% 54.09% 54.61% 54.44% 53.97% 46.02% 49.83% -
ROE 11.12% 10.72% 10.99% 10.97% 10.64% 9.04% 10.01% -
Per Share
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
RPS 483.20 467.54 470.01 460.95 445.75 438.74 437.06 6.91%
EPS 176.80 166.80 169.47 166.20 159.20 131.80 145.47 13.87%
DPS 52.00 40.00 53.33 26.00 52.00 38.00 50.67 1.74%
NAPS 15.88 15.55 15.41 15.10 14.91 14.52 14.48 6.34%
Adjusted Per Share Value based on latest NOSH - 1,147,516
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
RPS 487.56 471.55 473.65 466.13 450.75 443.66 441.97 6.75%
EPS 178.25 168.09 170.74 167.54 160.47 132.78 146.63 13.89%
DPS 52.47 40.34 53.75 26.29 52.58 38.43 51.24 1.59%
NAPS 16.0232 15.6833 15.5293 15.2696 15.0775 14.6831 14.6427 6.18%
Price Multiplier on Financial Quarter End Date
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
Date 28/09/18 29/06/18 30/03/18 29/12/17 29/09/17 30/06/17 31/03/17 -
Price 19.30 18.00 19.26 17.88 16.60 16.80 15.90 -
P/RPS 3.99 3.85 4.10 3.88 3.72 3.83 3.64 6.30%
P/EPS 10.92 10.80 11.37 10.79 10.46 12.79 10.97 -0.30%
EY 9.15 9.26 8.80 9.27 9.56 7.82 9.12 0.21%
DY 2.69 2.22 2.77 1.45 3.13 2.26 3.19 -10.73%
P/NAPS 1.22 1.16 1.25 1.18 1.11 1.16 1.10 7.13%
Price Multiplier on Announcement Date
30/09/18 30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 CAGR
Date 28/11/18 28/08/18 30/05/18 26/02/18 30/11/17 24/08/17 29/05/17 -
Price 19.18 18.60 18.50 18.46 16.06 16.70 16.42 -
P/RPS 3.97 3.98 3.94 4.00 3.60 3.81 3.76 3.68%
P/EPS 10.86 11.16 10.92 11.14 10.12 12.72 11.32 -2.72%
EY 9.21 8.96 9.16 8.98 9.88 7.86 8.83 2.84%
DY 2.71 2.15 2.88 1.41 3.24 2.28 3.09 -8.36%
P/NAPS 1.21 1.20 1.20 1.22 1.08 1.15 1.13 4.66%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment